減少副作用 標靶治療 獵殺肺癌細胞Target to reduce the side effects of the treatment of lung cancer-killing cells

減少副作用 標靶治療 獵殺肺癌細胞 ●肺癌很難早期發現，一旦出現較明顯的症狀大多已是晚期，無法以手術切除，藥物治療非常關鍵，新一代的標靶藥物不斷推陳出新，使得對抗癌症又多了一項利器，也讓肺癌治療的瓶頸有重大突破。 命中 抑制癌細胞生長 中研院院士彭汪嘉康指出，所謂「標靶療法」是針對癌細胞之所以突變、增殖或擴散的機制，透過分子生物技術直接阻斷腫瘤細胞的生長與修復能力，或抑制腫瘤中的血管新生，從而防止腫瘤的轉移。她說，這種療法如同導彈直接命中目標，較傳統化療「散彈打鳥」方式，可達到有效殺死癌細胞，也大幅減少副作用。 阻斷 防腫瘤擴散轉移 目前，台灣核准臨床用於治療肺癌的標靶藥物，便是直接阻斷腫瘤生長訊息傳遞的小分子物質，也就是直接抑制上皮生長因子接受體(EGFR)酪胺酸激酉每的活性，便可壓抑腫瘤的生長與擴散。 台灣林口長庚醫院胸腔內科系主任郭漢彬表示，包括大腸直腸癌、肺癌和頭頸部癌症，都與EGFR的過度活化有關，因此，若能在細胞外直接阻斷EGFR，讓癌細胞趨於死亡。 肺腺癌 艾瑞莎效果較佳 這類上皮生長因子接受體抑制劑，有「艾瑞莎」（Iressa）和「得舒緩」（Tarceva）兩種，在台灣僅當第二線使用，且規定患者必須是先前接受化學治療，但仍局部惡化或轉移的肺腺癌病人。 不過，香港中文大學教授墨唐尼在第33屆歐洲腫瘤醫學會表示，雖然艾瑞莎和得舒緩的作用機轉類似，但根據最近在歐洲腫瘤醫學會所發表的一項IPSAA研究證實，艾瑞莎在臨床治療上，對於某些特定族群，包括上皮生長因子受體特定位置有突變者、東方女性、非抽菸者，以及屬於肺腺癌的患者，效果較佳。 整體療效 優於傳統化療 參與這項跨國研究的墨唐尼表示，對於肺腺癌病人而言，艾瑞莎不論在整體療效、生活品質的改善，比起傳統化療要佳。 郭漢彬說，得舒緩的適用對象，比較不受個別基因活性變化的影響，且對於肺腺癌及鱗狀細胞肺癌，不分男女性別，甚至抽菸者都有效果。 癌思停 突破一年存活瓶頸 前年10月美國食品暨藥物管理局也已批准「癌思停」（Avastin），用於治療肺癌。 台北榮總胸腔腫瘤科主任蔡俊明表示，醫界研究發現，腫瘤細胞為了存活壯大，會分泌血管新生因子，以便形成新的血管，以便輸送源源不絕的養分，因此血管越密集，腫瘤越惡性；而血管新生抑制劑便是直接切斷腫瘤的養分供應，餓死癌細胞。 蔡俊明說，過去肺癌病人一旦被醫師診斷晚期肺癌的病人，在傳統化療藥物治療，根本無法突破中位存活期一年的瓶頸，而癌思停卻是第一個打破存活期只有一年的籓籬。（詹建富） 2008-10-19 Target to reduce the side effects of the treatment of lung cancer-killing cells ● very difficult for the early detection of lung cancer, in the event of the more obvious symptoms is the most advanced, can not be removed by surgery, medication is key to target a new generation of drugs continues to introduce new measures to combat cancer makes more of a weapon, but also There are bottlenecks in the treatment of lung cancer a major breakthrough. Hit inhibit cancer cell growth Academia Sinica Jacqueline Whang-Peng pointed out that the so-called "target therapy" is the reason why cancer cells for mutations, or the spread of proliferation mechanism, molecular biological technology through direct blocking tumor cell growth and repair, or inhibition of tumor angiogenesis In order to prevent tumor metastasis. She said that such therapy as a direct missile hit the target, the more traditional chemotherapy, "Da Niao shot" approach can be achieved effectively kill cancer cells, but also significantly reduce the side effects. Blocking the spread of anti-tumor metastasis At present, Taiwan approved for the treatment of lung cancer clinical target drugs to block tumor growth is a direct message of the small molecule material, which is directly inhibit epidermal growth factor receptor (EGFR) tyrosine stimulated the enzyme activity, it is May suppress tumor growth and proliferation. Taiwan's Chang Gung Memorial Hospital Head of the Department of Thoracic Medicine, said Han-Pin Kuo, including colorectal cancer, lung cancer and head and neck cancer, with over-activation of EGFR, therefore, if the cell block foreign direct EGFR, so that cancer cells tend to death. Aretha effects of lung cancer better This type of epithelial growth factor receptor inhibitors, "Aretha" (Iressa) and the "have to ease" (Tarceva) are in Taiwan only if the second line, and must be provided for patients with prior chemotherapy, but Still deteriorating or partial transfer of lung cancer patients. However, the Chinese University of Hong Kong and Mexico, a professor at the Downey 33rd tumor of the European Medical Association said that while Aretha and ease of a mechanism similar to the role, but according to a recent medical oncology in Europe, published by a research IPSAA confirmed that the Al Aretha in the clinical treatment for certain ethnic groups, including the epithelial growth factor receptor mutation have a specific location, the Oriental women, non-smokers, as well as belonging to the lung cancer patients, and better results. The overall effect is better than traditional chemotherapy To participate in the study of cross-border Mexico, said Downey, for lung cancer patients, regardless of Aretha in the overall efficacy, quality of life improvement, compared with traditional chemotherapy to good. Han-Pin Kuo said that the object was to ease the application of relatively individual from the impact of changes in gene activity, and for lung adenocarcinoma and squamous cell lung cancer, regardless of gender, and even those who have the effect of smoking. Think of to stop cancer Breakthrough year survival bottleneck The year before last October the U.S. Food and Drug Administration also has approved the "cancer stop thinking" (Avastin), for the treatment of lung cancer. Taipei Veterans General Hospital, director of thoracic oncology Chun-Ming Tsai said that the medical community found that the survival of tumor cells to grow, secrete angiogenesis factor, in order to form new blood vessels, in order to transport an endless supply of nutrients, so the more intensive blood vessels, the more malignant tumor ; And angiogenesis inhibitors that cut off direct nutrient supply to tumors, cancer cells starve to death. Chun-Ming Tsai said that in the past, if lung cancer patients diagnosed with advanced lung cancer patients in the traditional chemotherapy treatment, could not break through the median survival time of the year bottleneck, and the cancer is to stop thinking of the first to break the one-year survival is only big winnow basket Lei. (Zhan Jian Fu) 2008-10-19 View more information, see the World Journal reported that e-ePaper

瀏覽更多新聞，請看世界日報電子報 ePaper。